New anticoagulant therapy

Annual Review of Medicine

Volumn 56, Issue , 2005, Pages 63-77

  Linkins, Lori Ann ^a   Weitz, Jeffrey I ^a  

^a HENDERSON RESEARCH CENTRE   (Canada)

Author keywords

Factor Va and VIIIa inhibitors; Factor VIIa tissue factor inhibitors; Factor Xa inhibitors; Thrombin inhibitors

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; ANTICOAGULANT PROTEIN; ANTIVITAMIN K; ARGATROBAN; BLOOD CLOTTING FACTOR 7A INHIBITOR; DABIGATRAN ETEXILATE; DALTEPARIN; DROTRECOGIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRUDIN; HIRULOG; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; LY 517717; MELAGATRAN; NEMATODE ANTICOAGULANT PEPTIDE; PLACEBO; RAZAXABAN; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; RIVAROXABAN; THROMBOMODULIN; UNCLASSIFIED DRUG; WARFARIN; XIMELAGATRAN;

ADULT; AGED; ANTICOAGULATION; ARTERY THROMBOSIS; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; HEART ATRIUM FIBRILLATION; HEART MUSCLE ISCHEMIA; HUMAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; UNSTABLE ANGINA PECTORIS; VEIN THROMBOSIS;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ANTITHROMBIN III; CLINICAL TRIALS; DRUGS, INVESTIGATIONAL; FACTOR VA; FACTOR VIIA; FACTOR VIIIA; HUMANS; LIPOPROTEINS; THROMBIN; THROMBOSIS;

EID: 14544275123     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.56.082103.104708     Document Type: Review

References (47)

1. Abraham E, Reinhart K, Svoboda P, et al. 2001. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit. Care Med. 29: 2081-89
2. Abraham E, Reinhart K, Opal S, for the OPTIMIST Trial Study Group. 2003. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290:238-47
3. Stassens P, Bergum PW, Gansemans Y, et al. 1996. Anticoagulant repertoire of the hookworm Ancylostoma caninum. Proc. Natl. Acad. Sci. USA 93:2149-54
4. Lee A, Agnelli G, Buller H, et al. 2001. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation 104:74-78
5. Taylor FB Jr. 1996. Role of tissue factor and factor VIIa in the coagulant and inflammatory response to LD100 Escherichia coli in the baboon. Haemostasis 26:83-91
6. Jang Y, Guzman LA, Lincoff AM, et al. 1995. Influence of blockade at specific levels of the coagulant cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 92:3041-50
7. Lincoff AM. 2000. First clinical investigation of a tissue-factor inhibitor administered during percutaneous coronary revascularization: a randomized, double-blinded, dose-escalation trial-assessing safety and efficacy of FFR-FVIIa in percutaneous transluminal coronary angioplasty (ASIS) trial. J. Am. Coll. Cardiol. 36:312 (Abstr.)
8. Boneu B, Necciari J, Cariou R, et al. 1995. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/ORG31540) with high affinity to antithrombin III in man. Thromb. Haemost. 74:1468-73
9. Bijsterveld NR, Moons AH, Boekholdt SM, et al. 2002. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 106:2550-54
10. Turpie AG, Eriksson BI, Bauer KA, Lassen MR. 2003. New pentasaccharides for the prophylaxis of venous thromboembolism: clinical studies. Chest 124:371S-78S
11. Eriksson BI, Lassen MR, PENTasaccharide in Hip-FRAture Surgery Plus Investigators. 2003. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch. Intern. Med. 163:1337-42
12. Prandoni P, Bruchi O, Sabbion P, et al. 2002. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Arch. Intern. Med. 162:1966-71
13. Hull RD, Pineo GF, Francis C, et al. 2000. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. Arch. Intern. Med. 160: 2208-15
14. Cohen AT, Bailey CS, Alikhan R, Cooper DJ. 2001. Extended thromboprophylaxis with low molecular weight heparin reduces symptomatic venous thromboembolism following lower limb arthroplasty-a meta-analysis. Thromb. Haemost. 85:940-41
15. Eikelboom JW, Quinlan DJ, Douketis JD. 2001. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 358:9-15
16. Cohen AT, Gallus AS, Lassen MR, et al. 2003. Fondaparinux vs. placebo for the prevention of venous thromboembolism in acutely ill medical patients (ARTEMIS). J. Thromb. Haemost. 1(Suppl. 1):P2046 (Abstr.)
17. Agnelli G, Bergqvist D, Cohen A, et al. 2003. A randomized double-blind study to compare the efficacy and safety of fondaparinux with dalteparin in the prevention of venous thromboembolism after high-risk abdominal surgery: the PEGASUS Study. J. Thromb. Haemost. 1(Suppl. 1):OC006 (Abstr.)
18. Buller HR, Davidson BL, Decousus H, et al. 2004. Fondaparinux or enoxaparin for initial treatment of symptomatic deep vein thrombosis: a randomized trial. Ann. Intern. Med. 140:867-73
19. The MATISSE Investigators. 2003. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N. Engl. J. Med. 349:1695-702
20. Ferguson JJ. 2002. Meeting highlights-American Heart Association scientific sessions 2001. Circulation 105:e37-e41
21. Coussement PK, Bassand JP, Convens C, et al. 2001. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur. Heart J. 22: 1716-24
22. Herbert JM, Herault JP, Bernat A, et al. 1998. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 91:4197-205
23. PERSIST Investigators. 2004. A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis: a phase II evaluation. J. Thromb. Haemost. 2:47-53
24. Alexander JH, Dyke CK, Yang H, et al. 2004. Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot. J. Thromb. Haemost. 2:234-41
25. Lassen MR, Davidson BL, Gallus A, et al. 2003. A phase II randomized, double-blind, five-arm, parallel-group, dose-response study of a new oral directly-acting factor Xa inhibitor, razaxaban, for the prevention of deep vein thrombosis in knee replacement surgery. Blood 102:41 (Abstr.)
26. Ettingshausen CE, Veldmann A, Beeg T, et al. 1999. Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans. Semin. Thromb. Hemost. 25:537-41
27. White B, Livingstone W, Murphy C, et al. 2000. An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood 96:3719-24
28. Bernard GR, Vincent JL, Laterre PF, et al. 2001. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344:699-709
29. Kearon C, Comp C, Douketis D, et al. 2003. A dose-response study of a recombinant human soluble thrombomodulin (ART-123) for prevention of venous thromboembolism after unilateral total hip replacement. J. Thromb. Haemost. 1(Suppl. 1): OC330 (Abstr.)
30. Gustafsson D, Nystrom JE, Carlsson S, et al. 2001. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb. Res. 101:171-81
31. Elg M, Borjesson I, Pehrsson S, et al. 2000. Feiba™ reversed bleeding times prolonged by high doses of a thrombin inhibitor and was not prothrombotic. Blood 96:13911 (Abstr.)
32. Ulvinge J-C, Berntsson P, Bostrom SL. 2000. Melagatran-induced inhibition of thrombin generation is reversed by Feiba™. Blood 96:13917 (Abstr.)
33. Eriksson BI, Bergqvist D, Kalebo P, et al. 2002. Melagatran for thrombin inhibition in orthopaedic surgery. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 360:1441-47
34. Eriksson BI, Agnelli G, Cohen AT, et al. 2003. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J. Thromb. Haemost. 1:2490-96
35. Colwell CW, Berkowitz SD, Davidson BL, et al. 2003. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J. Thromb. Haemost. 1:2119-30
36. Francis CW, Berkowitz SD, Comp PC, et al. 2003. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N. Engl. J. Med. 349:1703-12
37. Colwell CW, Berkowitz SD, Comp PC, et al. 2003. Randomized, double-blind comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement (TKR): EXULTB. Blood 102:14 (Abstr.)
38. Eriksson H, Wahlander K, Gustafsson D, et al. 2003. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J. Thromb. Haemost. 1:41-47
39. Huisman MV on behalf of the THRIVE Investigators. 2003. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: a randomized, double-blind, multinational study. J. Thromb. Haemost. 1(Suppl. 1):OC003 (Abstr.)
40. Schulman S, Wahlander K, Lundstrom T, et al.; THRIVE III Investigators. 2003. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N. Engl. J. Med. 349:1713-21
41. Petersen P, Grind M, Adler J; SPORTIF II Investigators. 2003. Ximelagatran versus warfarin for stroke prevention in patients with non-valvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. J. Am. Coll. Cardiol. 41:1445-51
42. Halperin JL; Executive Steering Committee, SPORTIF III and V Study Investigators. 2003. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am. Heart J. 146:431-38
43. Olsson SB; SPORTIF III Investigators. 2003. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 362:1691-98
44. Halperin J. 2003. Stroke prevention using the oral DTI ximelagatran in patients with nonvalvular AF (SPORTIF V) trial. Presented at Am. Heart Assoc. Meet., Orlando, FL, Nov. 9-12
45. Wallentin L, Wilcox R, Weaver D, et al. 2003. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 362:789-97
46. Gustafsson D. 2003. Oral direct thrombin inhibitors in clinical development. J. Intern. Med. 254:322-34
47. Mungall D. 2002. BIBR-1048 Boehringer Ingelheim. Curr. Opin. Investig. Drugs 3:905-7